On November 13, during a panel discussion at the Shanghai Stock Exchange International Investors Conference, industry leaders debated the question: "Can China produce a world-class pharmaceutical company?" The session was moderated by Yu Wenxin, Deputy Director of Guotai Haitong Securities Research Institute.

Gao Fei, Chairman and General Manager of Hangzhou Alltest Biotech Co., Ltd., stated that world-class companies "will undoubtedly emerge" in China. In his view, key factors for achieving global leadership include industry opportunities, international conditions, a company's innovation capabilities—especially sustained innovation—and a collaborative team culture.

Xiao Zhihua, Chairman of Shanghai OPM Biosciences Co., Ltd., noted that in an era of deglobalization, Chinese companies face greater challenges in becoming truly global enterprises. However, he emphasized that "world-class companies will inevitably emerge," as Chinese firms possess breakthrough potential.

Zhang Lianshan, Global R&D President of Jiangsu Hengrui Pharmaceuticals Co., Ltd., highlighted the importance of confidence and policy support. He stressed that for biopharmaceutical companies to create global value, they must first establish a strong foundation in the domestic market, with sustained government policy backing playing a crucial role.

The panel concluded that with improving innovation capabilities and continuous policy refinement, China's pharmaceutical industry has the potential to cultivate world-class enterprises in the future.